{
  "paper_metadata": {
    "pmid": "34749799",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted information on BRCA2 variants, including clinical significance, penetrance data, and individual records."
  },
  "variants": [
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.Asp935Asn",
      "protein_notation": "p.Asp935Asn",
      "genomic_position": null,
      "clinical_significance": "VUS",
      "patients": {
        "count": 25,
        "demographics": "Patients suffering from high-grade serous ovarian cancer",
        "phenotype": "High-grade serous ovarian cancer"
      },
      "penetrance_data": {
        "total_carriers_observed": 25,
        "affected_count": null,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": null,
        "age_dependent_penetrance": []
      },
      "individual_records": [],
      "functional_data": {
        "summary": "Functional impact evaluated using CRISPR-Cas9 genome editing.",
        "assays": [
          "CRISPR-Cas9 genome editing",
          "next-generation sequencing"
        ]
      },
      "segregation_data": null,
      "population_frequency": null,
      "evidence_level": "Moderate",
      "source_location": "Methods, Variant Selection",
      "additional_notes": "Variant classified as VUS based on functional testing.",
      "key_quotes": [
        "'We first evaluated the functional impact of 26 BRCA1 and 7 BRCA2 variants...'"
      ]
    },
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.Ser1882X",
      "protein_notation": "p.Ser1882X",
      "genomic_position": null,
      "clinical_significance": "VUS",
      "patients": {
        "count": 25,
        "demographics": "Patients suffering from high-grade serous ovarian cancer",
        "phenotype": "High-grade serous ovarian cancer"
      },
      "penetrance_data": {
        "total_carriers_observed": 25,
        "affected_count": null,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": null,
        "age_dependent_penetrance": []
      },
      "individual_records": [],
      "functional_data": {
        "summary": "Functional impact evaluated using CRISPR-Cas9 genome editing.",
        "assays": [
          "CRISPR-Cas9 genome editing",
          "next-generation sequencing"
        ]
      },
      "segregation_data": null,
      "population_frequency": null,
      "evidence_level": "Moderate",
      "source_location": "Methods, Variant Selection",
      "additional_notes": "Variant classified as VUS based on functional testing.",
      "key_quotes": [
        "'We first evaluated the functional impact of 26 BRCA1 and 7 BRCA2 variants...'"
      ]
    },
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.Val2728Ile",
      "protein_notation": "p.Val2728Ile",
      "genomic_position": null,
      "clinical_significance": "VUS",
      "patients": {
        "count": 25,
        "demographics": "Patients suffering from high-grade serous ovarian cancer",
        "phenotype": "High-grade serous ovarian cancer"
      },
      "penetrance_data": {
        "total_carriers_observed": 25,
        "affected_count": null,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": null,
        "age_dependent_penetrance": []
      },
      "individual_records": [],
      "functional_data": {
        "summary": "Functional impact evaluated using CRISPR-Cas9 genome editing.",
        "assays": [
          "CRISPR-Cas9 genome editing",
          "next-generation sequencing"
        ]
      },
      "segregation_data": null,
      "population_frequency": null,
      "evidence_level": "Moderate",
      "source_location": "Methods, Variant Selection",
      "additional_notes": "Variant classified as VUS based on functional testing.",
      "key_quotes": [
        "'We first evaluated the functional impact of 26 BRCA1 and 7 BRCA2 variants...'"
      ]
    },
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.Gln2829Arg",
      "protein_notation": "p.Gln2829Arg",
      "genomic_position": null,
      "clinical_significance": "VUS",
      "patients": {
        "count": 25,
        "demographics": "Patients suffering from high-grade serous ovarian cancer",
        "phenotype": "High-grade serous ovarian cancer"
      },
      "penetrance_data": {
        "total_carriers_observed": 25,
        "affected_count": null,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": null,
        "age_dependent_penetrance": []
      },
      "individual_records": [],
      "functional_data": {
        "summary": "Functional impact evaluated using CRISPR-Cas9 genome editing.",
        "assays": [
          "CRISPR-Cas9 genome editing",
          "next-generation sequencing"
        ]
      },
      "segregation_data": null,
      "population_frequency": null,
      "evidence_level": "Moderate",
      "source_location": "Methods, Variant Selection",
      "additional_notes": "Variant classified as VUS based on functional testing.",
      "key_quotes": [
        "'We first evaluated the functional impact of 26 BRCA1 and 7 BRCA2 variants...'"
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 4,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All extracted variants are classified as VUS based on functional testing."
  }
}